Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

AVI-4126 proves safe in PKD patients

Nov. 25, 2002

Ono reports prostanoid EP1 antagonists for urinary incontinence, pain, etc.

Nov. 22, 2002

Series of PDE5 inhibitors identified by Pfizer researchers

Nov. 21, 2002

Selective p38alpha MAPK inhibitor NPC-31145 improves outcome in glomerulonephritis

Nov. 19, 2002

First approval obtained for Cialis

Nov. 15, 2002

Novel substance P antagonists covered by Takeda patent

Nov. 15, 2002

New 5-HT2C agonists for erectile dysfunction and other disorders under study at Yamanouchi

Nov. 15, 2002

Accelerated approval plan for KRX-101

Nov. 14, 2002

Positive results from TA-1790 erectile dysfunction study

Nov. 13, 2002

Health Canada approves irbesartan for diabetic renal disease

Nov. 13, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...